Hoesli Rebecca C, Wingo Melissa L, Bastian Robert W
Bastian Voice Institute, Downers Grove, Illinois, USA.
OTO Open. 2020 Jun 29;4(2):2473974X20938342. doi: 10.1177/2473974X20938342. eCollection 2020 Apr-Jun.
To report the percentage of patients with symptom relief 6 or more months after botulinum toxin injection into the cricopharyngeus muscle for retrograde cricopharyngeus dysfunction (R-CPD).
Retrospective case series of consecutively treated patients.
Tertiary care laryngology clinic.
A review was performed of the first 200 patients who were diagnosed with R-CPD and treated with botulinum toxin injection into the cricopharyngeus muscle by a single surgeon. The study group was limited to those for whom a minimum of 6 months has elapsed since the injection. Items assessed were efficacy, safety, complications, and duration of benefit.
Of 200 patients treated, (99.5%) gained the ability to burp and 95% experienced relief of the cardinal symptoms of R-CPD: inability to belch, socially awkward gurgling noises, abdominal/chest pressure and bloating, and excessive flatulence. For those who experienced relief, 159 (79.9%) maintained a satisfactory ability to burp after 6 months. Of those who did not maintain the ability, 12 underwent a second injection, 1 patient underwent 3 subsequent injections, and 3 patients underwent partial myotomy. No patients experienced complications of botulinum toxin injection itself, and 4 patients had complications from esophagoscopy or anesthesia.
In a case series of 200 patients with retrograde cricopharyngeus dysfunction, 99% experienced relief of the cardinal symptoms and 79.9% experienced lasting relief of their symptoms beyond pharmacologic duration of action after a single injection of botulinum toxin into the cricopharyngeus muscle. Relief can be reestablished in the remainder via additional injection or cricopharyngeus myotomy.
报告肉毒杆菌毒素注射至环咽肌治疗逆行性环咽肌功能障碍(R-CPD)6个月或更长时间后症状缓解的患者百分比。
连续治疗患者的回顾性病例系列。
三级护理喉科诊所。
对首批200例被诊断为R-CPD并由一名外科医生进行肉毒杆菌毒素注射至环咽肌治疗的患者进行回顾。研究组仅限于自注射后至少已过去6个月的患者。评估的项目包括疗效、安全性、并发症和受益持续时间。
在接受治疗的200例患者中,99.5%能够打嗝,95%的患者R-CPD的主要症状得到缓解:无法嗳气、社交尴尬的咕噜声、腹部/胸部压力和腹胀以及过度肠胃胀气。对于症状缓解的患者,159例(79.9%)在6个月后仍保持满意的打嗝能力。在那些未保持该能力的患者中,12例接受了第二次注射,1例患者随后接受了3次注射,3例患者接受了部分肌切开术。没有患者出现肉毒杆菌毒素注射本身的并发症,4例患者因食管镜检查或麻醉出现并发症。
在一个包含200例逆行性环咽肌功能障碍患者的病例系列中,99%的患者主要症状得到缓解,79.9%的患者在向环咽肌单次注射肉毒杆菌毒素后症状缓解持续时间超过药物作用时间。其余患者可通过额外注射或环咽肌肌切开术重新获得缓解。